Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Stavudine - Lamivudine - Nevirapine
2. Stavudine, Lamivudine, Nevirapine Drug Combination
3. Triomune
1. 811471-91-7
2. 4-amino-1-[(2r,5s)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one;2-cyclopropyl-7-methyl-2,4,9,15-tetrazatricyclo[9.4.0.03,8]pentadeca-1(11),3,5,7,12,14-hexaen-10-one;1-[(2r,5s)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]-5-methylpyrimidine-2,4-dione
3. Lamivudine; Stavudine; Nevirapine
4. Lamivudine/nevirapine/stavudine
5. Stavudine, Lamivudine And Nevirapine
6. Lamivudine Mixture With Nevirapine And Stavudine
7. Stv & Lmv & Nvp
8. Lamivudine, Nevirapine, And Stavudine Fixed-dose Tablet
9. Nevirapine & Lamivudine & Stavudine
10. 11-cyclopropyl-4-methyl-5,11-dihydro-6h-dipyrido[2,3-e:3',2'-b][1,4]diazepin-6-one & (-)-(2'r,5's)-1-[2'-hydroxymethyl-5'-(1,3-oxathiolanyl)]cytosine & Thymidine, 2',3'-didehydro-, 3'-deoxy-
11. 4-amino-1-[(2r,5s)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one; 11-cyclopropyl-4-methyl-5h-dipyrido[[?],[?]][1,4]diazepin-6-one; 1-[(2r,5s)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]-5-methyl-pyrimidine-2,4-dione
| Molecular Weight | 719.8 g/mol |
|---|---|
| Molecular Formula | C33H37N9O8S |
| Hydrogen Bond Donor Count | 5 |
| Hydrogen Bond Acceptor Count | 12 |
| Rotatable Bond Count | 5 |
| Exact Mass | 719.24858035 g/mol |
| Monoisotopic Mass | 719.24858035 g/mol |
| Topological Polar Surface Area | 250 Ų |
| Heavy Atom Count | 51 |
| Formal Charge | 0 |
| Complexity | 1120 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 4 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 3 |
| 1 of 2 | |
|---|---|
| Drug Name | Lamivudine; stavudine; nevirapine |
| Active Ingredient | stavudine; Lamivudine; nevirapine |
| Dosage Form | Tablet; Tablet, dispersible |
| Route | oral |
| Strength | 100mg; 6mg; 30mg; 200mg; 150mg; 12mg; 50mg; 30mg; 40mg; 60mg |
| Market Status | Tentative Approval |
| Company | Cipla |
| 2 of 2 | |
|---|---|
| Drug Name | Lamivudine; stavudine; nevirapine |
| Active Ingredient | stavudine; Lamivudine; nevirapine |
| Dosage Form | Tablet; Tablet, dispersible |
| Route | oral |
| Strength | 100mg; 6mg; 30mg; 200mg; 150mg; 12mg; 50mg; 30mg; 40mg; 60mg |
| Market Status | Tentative Approval |
| Company | Cipla |
Anti-HIV Agents
Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS. (See all compounds classified as Anti-HIV Agents.)
Reverse Transcriptase Inhibitors
Inhibitors of reverse transcriptase (RNA-DIRECTED DNA POLYMERASE), an enzyme that synthesizes DNA on an RNA template. (See all compounds classified as Reverse Transcriptase Inhibitors.)
J - Antiinfectives for systemic use
J05 - Antivirals for systemic use
J05A - Direct acting antivirals
J05AR - Antivirals for treatment of hiv infections, combinations
J05AR07 - Stavudine, lamivudine and nevirapine
Digital Content 
NEWS #PharmaBuzz
ABOUT THIS PAGE
A Stavudine, Lamivudine, Nevirapine Drug Combination manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Stavudine, Lamivudine, Nevirapine Drug Combination, including repackagers and relabelers. The FDA regulates Stavudine, Lamivudine, Nevirapine Drug Combination manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Stavudine, Lamivudine, Nevirapine Drug Combination API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Stavudine, Lamivudine, Nevirapine Drug Combination supplier is an individual or a company that provides Stavudine, Lamivudine, Nevirapine Drug Combination active pharmaceutical ingredient (API) or Stavudine, Lamivudine, Nevirapine Drug Combination finished formulations upon request. The Stavudine, Lamivudine, Nevirapine Drug Combination suppliers may include Stavudine, Lamivudine, Nevirapine Drug Combination API manufacturers, exporters, distributors and traders.
Stavudine, Lamivudine, Nevirapine Drug Combination Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Stavudine, Lamivudine, Nevirapine Drug Combination GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Stavudine, Lamivudine, Nevirapine Drug Combination GMP manufacturer or Stavudine, Lamivudine, Nevirapine Drug Combination GMP API supplier for your needs.
A Stavudine, Lamivudine, Nevirapine Drug Combination CoA (Certificate of Analysis) is a formal document that attests to Stavudine, Lamivudine, Nevirapine Drug Combination's compliance with Stavudine, Lamivudine, Nevirapine Drug Combination specifications and serves as a tool for batch-level quality control.
Stavudine, Lamivudine, Nevirapine Drug Combination CoA mostly includes findings from lab analyses of a specific batch. For each Stavudine, Lamivudine, Nevirapine Drug Combination CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Stavudine, Lamivudine, Nevirapine Drug Combination may be tested according to a variety of international standards, such as European Pharmacopoeia (Stavudine, Lamivudine, Nevirapine Drug Combination EP), Stavudine, Lamivudine, Nevirapine Drug Combination JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Stavudine, Lamivudine, Nevirapine Drug Combination USP).
LOOKING FOR A SUPPLIER?
